Vitamin B12
Vitamin B12: What 248 human studies show, including 93 randomized controlled trials – organized by area of application and strength of evidence.
We evaluated 248 human studies on Vitamin B12, including 93 randomised controlled trials and 56 meta-analyses or systematic reviews; the controlled studies include 14,539 participants in total. As of 3 October 2026.
1. What Is Vitamin B12? Occurrence, Origin and Forms
Vitamin B12 (cobalamin) is a water-soluble vitamin with a cobalt atom at its centre. The body needs it for blood formation, for the nerves and for breaking down homocysteine; it is absorbed in the small intestine only together with intrinsic factor from the stomach.
Only microorganisms make vitamin B12. It occurs in meaningful amounts in animal foods such as meat, liver, fish, eggs and dairy products; plant foods provide hardly any usable vitamin B12.
For supplements, vitamin B12 is produced by bacteria (fermentation). There are tablets, lozenges and sublingual tablets, drops, nasal sprays and intramuscular injections.
Forms and Preparations Studied
- Cyanocobalamin
- Methylcobalamin and adenosylcobalamin
- Hydroxocobalamin, mostly as injection
- Tablets, sublingual tablets, nasal spray and injection
- Vitamin B12 combined with folic acid and vitamin B6
Not covered on this page:
- Studies that measure vitamin B12 blood levels only as a side finding without studying intake or supplementation
2. What Does Vitamin B12 Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Status in vegan diets, older age and with medication | mostly improved | high | 18 meta-analyses · 24 controlled · 43 other | 2,795 |
| Nerves and nerve damage | mostly improved | high | 8 meta-analyses · 24 controlled · 26 other | 2,302 |
| Homocysteine, heart and blood vessels | mostly improved | high | 8 meta-analyses · 24 controlled · 27 other | 2,467 |
| Memory and mood | mixed | high | 7 meta-analyses · 16 controlled · 18 other | 1,756 |
| Blood formation and anaemia | mixed | high | 6 meta-analyses · 8 controlled · 14 other | 2,163 |
| Pregnancy and children | mixed | high | 3 meta-analyses · 4 controlled · 20 other | 1,599 |
| Other outcomes | mostly improved | high | 8 meta-analyses · 53 controlled · 45 other | 9,028 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Vitamin B12, Status in Vegan Diets, Older Age and with Medication: Human Studies
With a vegan diet without supplementation, reviews and one controlled trial found poorer vitamin B12 blood levels 4851115. Even a partial replacement of animal proteins with plant proteins lowered vitamin B12 status 141. With long-term use of omeprazole, vitamin B12 levels after twelve months were lower than with other acid inhibitors in a controlled trial 136. In metformin-treated type 2 diabetics with vitamin B12 deficiency, oral methylcobalamin or sucrosomial cyanocobalamin normalized the levels in one controlled trial each 91133. Vitamin B12 together with folic acid, sometimes also with vitamin B6, increased vitamin B12 blood levels in meta-analyses 2241. A salt enriched with iodine, iron, folic acid and other micronutrients provided inconsistent findings on vitamin B12 status 23. The strength of evidence is high; what remains open is how well the mostly short studies can be transferred to pregnant women, children or the very old.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Lotti et al. 2026 | meta-analysis · 48,626 participants | Lacto-ovo-vegetarian or vegan diet (vitamin B12 as nutrient); vs. Omnivorous diet | Vitamin B12 intake: worsened; Vitamin B12 deficiency in vegans: worsened |
| 5 Mazur et al. 2025 | meta-analysis · 6,098 participants | Vitamin B12 sublingual, oral or intramuscular; not reported; dose subgroup analysis showed no dose-response effect; vs. sublingual and oral versus intramuscular injection | Serum cobalamin: improved (pooled mean difference = +402.6 pg/mL; 95% CI: 293.6 to 511.5; p < 0.001); Cobalamin: oral/sublingual versus intramuscular: no difference (p = 0.270) |
| 6 Abdelwahab et al. 2024 | meta-analysis · 4,275 participants | Vitamin B12 (various administration routes); vs. Oral vs. intramuscular vs. sublingual | Vitamin B12 levels: no difference (MD = 94.09 and 43.31 pg/mL) |
| 7 Larvie et al. 2026 | systematic review · 4,083 participants | Oral vitamin B12 supplementation, alone or with other micronutrients; 0.9 µg/day to 150 µg/day; 28 days to 31 months; vs. Placebo | Vitamin B12 deficiency: improved (ARD 56 fewer per 1000, 95% CI 68 fewer to 24 fewer; 1.8% versus 7.6%; RR 0.27, 95% CI 0.11 to 0.69); Total vitamin B12 concentrations: improved (MD 68.53 pmol/L, 95% CI 41.83 to 95.23) |
| 14 Finkelstein et al. 2024 | systematic review · 984 participants | oral vitamin B12 supplementation; 5 µg/day to 250 µg/day; 8–16 to 32–38 weeks, from 8–28 weeks' gestation; vs. placebo or no vitamin B12 supplementation | Maternal vitamin B12 deficiency: improved (25.9% versus 67.9%; RR 0.38, 95% CI 0.28 to 0.51); Total vitamin B12 concentrations: improved (MD 60.89 pmol/L, 95% CI 40.86 to 80.92) |
| 16 Shahid et al. 2025 | systematic review · 693 participants | Proton pump inhibitors (PPIs), not vitamin B12; at least 6 months, up to 12 months; vs. no PPI or baseline | Serum vitamin B12: worsened (12-18% reduction in serum vitamin B12 over 12 months) |
| 17 Ménétrier et al. 2023 | systematic review · 574 participants | No B12 administration; measurement of total B12, holoTC, tHcy, MMA; vs. No comparison; prevalence of abnormal laboratory values | Proportion with low total vitamin B12: unclear (42.2% (95% confidence interval 37.8-46.6%, n = 486)); Proportion with low holotranscobalamin: unclear (28.6% (7.5-49.6%, n = 21)) |
| 18 Wirthensohn et al. 2023 | systematic review · 292 participants | — | Maternal B12, exclusive breastfeeding and low-B12 maternal diet predicted infant B12, methylmalonic acid and total homocysteine: unclear |
Further studies in this area: 22 23 25 26 28 33 34 39 40 41 47 48 50 51 54 61 62 64 81 85 86 91 92 94 102 112 115 116 119 121 125 127 129 132 133 136 139 141 152 154 155 158 159 160 161 162 163 168 169 170 171 185 186 189 195 201 203 204 205 210 213 214 215 217 218 220 223 224 225 226 227 228 230 231 233 235 237
Vitamin B12, Nerves and Nerve Damage: Human Studies
In type 2 diabetes with neuropathy, nerve conduction, vibration perception and pain improved with oral methylcobalamin over one year, while they worsened with placebo 91. In another study, methylcobalamin worked as well as acetyl-L-carnitine 72. A meta-analysis found better nerve conduction when vitamin B12 was injected into acupuncture points rather than given otherwise 9. After foot or ankle surgery, complex regional pain syndrome occurred less often with methylcobalamin than with placebo 65. During chemotherapy, nerve damage developed less often with vitamin B12 than with placebo 130. In neurological symptoms due to vitamin B12 deficiency, several studies found improvements 203152. A review links a deficiency of vitamin B12 and other nutrients in vegan and vegetarian diets with a higher risk of mental decline 37. The findings are predominantly based on oral methylcobalamin preparations; combinations with alpha-lipoic acid and epalrestat, fasudil, prostaglandin E1, dapagliflozin, herbal medicines or Chinese patent medicine also showed improvements in meta-analyses 1011123246, but cannot be attributed to vitamin B12 alone. What remains open are the optimal form, the best route of administration and the effect in non-diabetic neuropathy.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Lee et al. 2022 | meta-analysis · 6,260 participants | oral methylcobalamin alone or with herbal medicines; vs. oral methylcobalamin alone | sensory nerve conduction velocity (SNCV): improved; motor nerve conduction velocity (MNCV): improved; total efficacy rate (TER): improved |
| 7 Larvie et al. 2026 | systematic review · 4,083 participants | Oral vitamin B12 supplementation, alone or with other micronutrients; 0.9 µg/day to 150 µg/day; 28 days to 31 months; vs. Placebo | Motor skill development (6 to 9 years, NEPSY-II): no difference |
| 9 Yu et al. 2026 | meta-analysis · 1,688 participants | vitamin B12 via acupoint injection; vs. other administration routes of vitamin B12 | clinical effectiveness proportion: improved (RR 1.28, 95% CI 1.22-1.35); peroneal nerve motor nerve conduction velocity: improved (MD 4.43, 95% CI 2.83-6.03); peroneal nerve sensory nerve conduction velocity: improved (MD 3.82, 95% CI 3.23-4.41) |
| 10 Ran et al. 2024 | meta-analysis · 1,153 participants | Mecobalamin plus alpha-lipoic acid and epalrestat; vs. Monotherapy or dual therapy with the same drugs | Therapeutic outcome (total efficacy): improved (odds ratio: 3.74; 95 % confidence interval: 2.57-5.45; p < 0.00001); Median motor nerve conduction velocity (MNCV): improved; Sensory nerve conduction velocity (SNCV): improved |
| 11 Jiang et al. 2018 | meta-analysis · 1,148 participants | Methylcobalamin alone or with fasudil; vs. Methylcobalamin monotherapy | clinical efficacy: improved (RR 1.26, 95% CI 1.17-1.35, P < .00001); median motor nerve conduction velocity: improved (MD 6.69, 95% CI 4.74-8.64, P < .00001); median sensory nerve conduction velocity: improved (MD 6.71, 95% CI 1.77-11.65, P = .008) |
| 12 Jiang et al. 2018 | meta-analysis · 1,136 participants | Methylcobalamin plus prostaglandin E1; vs. Prostaglandin E1 monotherapy | Clinical efficacy: improved (RR 1.25, 95% CI 1.18-1.32, P < .00001); Median motor nerve conduction velocity: improved (MD 6.29, 95% CI 4.63-7.94, P < .00001); Median sensory nerve conduction velocity: improved (MD 5.68, 95% CI 3.53-7.83, P < .00001) |
| 20 Blom et al. 2024 | systematic review · 50 participants | cobalamin (monotherapy); mean 2 months; vs. no control (case series) | Disappearance of other neuropsychiatric manifestations: improved (60%) |
| 31 Hamza et al. 2025 | systematic review | Vitamin B12 supplements, oral or intramuscular; vs. oral versus intramuscular administration; supplementation versus control | Neurological symptoms in overt deficiency: improved; Symptom scores in diabetic neuropathy: improved; Objective neurological measures in diabetic neuropathy: no difference |
Further studies in this area: 32 37 44 46 52 53 65 70 72 73 75 83 88 89 91 94 98 103 104 109 121 122 125 130 134 135 142 146 147 150 168 171 175 181 188 189 193 194 197 202 203 208 209 218 222 233 235 239 241 242
Vitamin B12, Homocysteine, Heart and Blood Vessels: Human Studies
In adults with vitamin B12 deficiency, the administration of vitamin B12 lowered the homocysteine blood level; oral and sublingual intake did not perform worse than intramuscular injection 531. Vitamin B12 together with folic acid, sometimes additionally with vitamin B6, also lowered homocysteine, among others in type 2 diabetes, mild cognitive impairment and Alzheimer's disease 222730354143. The strength of evidence is high, but many studies tested only the homocysteine blood level, not heart attacks or strokes.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Ulloque-Badaracco et al. 2023 | meta-analysis · 87,988 participants | Vitamin B12 (level measurement, no supplementation); vs. higher vs. lower vitamin B12 levels | Metabolic syndrome with higher vitamin B12 levels: improved (OR = 0.87; 95% CI: 0.81-0.93; p < 0.01); Metabolic syndrome with higher homocysteine levels: worsened (OR = 1.19; 95% CI: 1.14-1.24; p < 0.01); Metabolic syndrome with higher folate levels: no difference (OR = 0.83; 95% CI: 0.66-1.03; p = 0.09) |
| 5 Mazur et al. 2025 | meta-analysis · 6,098 participants | Vitamin B12 sublingual, oral or intramuscular; not reported; dose subgroup analysis showed no dose-response effect; vs. sublingual and oral versus intramuscular injection | Homocysteine: improved (pooled mean difference = -4.83 μmol/L; 95% CI: -6.55 to -3.11; p < 0.001); Homocysteine: oral/sublingual versus intramuscular: no difference (p = 0.485) |
| 6 Abdelwahab et al. 2024 | meta-analysis · 4,275 participants | Vitamin B12 (various administration routes); vs. Oral vs. intramuscular vs. sublingual | Homocysteine levels: no difference |
| 17 Ménétrier et al. 2023 | systematic review · 574 participants | No B12 administration; measurement of total B12, holoTC, tHcy, MMA; vs. No comparison; prevalence of abnormal laboratory values | Proportion with elevated homocysteine: unclear (79.7% (75.9-83.5%, n = 429)) |
| 22 Liu et al. 2026 | meta-analysis | Vitamin B12, alone or with folic acid and vitamin B6; vs. Randomized controlled trials of nutritional supplements | Blood homocysteine level: improved (varying improvements in blood biomarkers, including homocysteine, vitamin B12, and serum folate levels) |
| 27 Li et al. 2025 | systematic review | B vitamins (vitamin B6, vitamin B12, partly folate); vs. Control groups of included trials | Plasma homocysteine: improved (effectively reduce plasma homocysteine levels); Thrombotic risk: unclear (remains uncertain) |
| 30 Yin et al. 2025 | meta-analysis | Folic acid plus vitamin B12 (some with vitamin B6); vs. Control (placebo/no supplementation) | Serum homocysteine: improved (SMD = -2.77, 95% CI [-3.23, -2.30], P < 0.0001) |
| 31 Hamza et al. 2025 | systematic review | Vitamin B12 supplements, oral or intramuscular; vs. oral versus intramuscular administration; supplementation versus control | Homocysteine levels: improved |
Further studies in this area: 33 35 41 43 48 53 59 68 73 81 85 87 95 97 102 107 110 111 114 115 118 119 123 132 137 145 148 149 150 151 157 159 167 168 170 174 176 177 187 188 190 202 206 211 212 217 229 230 237 243 244
Vitamin B12, Memory and Mood: Human Studies
A systematic review reports that hallucinations in vitamin B12 deficiency improved with vitamin B12 alone 20. Another review links a good vitamin B12 status in pregnant women with better language, better memory and better thinking performance in the children 24. In possible mild cognitive impairment, vitamin B12 brought no advantage for memory and depressive symptoms in a meta-analysis 45. Also in children under twelve years, a systematic review found no difference in thinking performance 7. In adults with mild deficiency without symptoms, another review showed no advantages for thinking and nerves 31. Together with folic acid, the results were inconsistent. In Alzheimer's disease, a meta-analysis found a better MMSE value, but no difference in the ADAS-Cog value 43. In mild cognitive impairment, a randomized study found no difference overall, only with greater brain shrinkage in the left frontal area 68. In older adults, an advantage appeared only with higher blood levels of the omega-3 fatty acid DHA 74. The evidence strength is high, but the result is mixed: forms, groups and measures differ greatly, and it remains open which form and dose benefits whom.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 7 Larvie et al. 2026 | systematic review · 4,083 participants | Oral vitamin B12 supplementation, alone or with other micronutrients; 0.9 µg/day to 150 µg/day; 28 days to 31 months; vs. Placebo | Cognitive function (e.g. attention): no difference (SMD 0.09, 95% CI -0.10 to 0.28) |
| 20 Blom et al. 2024 | systematic review · 50 participants | cobalamin (monotherapy); mean 2 months; vs. no control (case series) | Full amelioration of hallucinations: improved (75%); Partial amelioration of hallucinations: improved (25%); Therapy-resistant hallucinations fully resolved under cobalamin monotherapy: improved (a quarter of the cases) |
| 24 Franco et al. 2026 | systematic review | Maternal vitamin B12 status or supplementation, with vitamin D and folic acid; vs. Children with adequate vs. inadequate maternal vitamin B12 status | Language, memory and cognitive performance: improved |
| 31 Hamza et al. 2025 | systematic review | Vitamin B12 supplements, oral or intramuscular; vs. oral versus intramuscular administration; supplementation versus control | Cognitive and neurological outcomes in subclinical deficiency: no difference |
| 41 Zhao et al. 2025 | meta-analysis | Vitamin B12 alone or with folate; vs. Network meta-analysis of several interventions | Cognitive decline: improved |
| 43 Lee et al. 2024 | meta-analysis | Vitamin B12 and folic acid; 6 months; vs. Placebo | MMSE score: improved (SMD = 0.21, 95% CI = 0.01 to 0.32, p = 0.04); ADAS-Cog score: no difference (SMD = 0.06, 95% CI = -0.22 to 0.33, p = 0.68) |
| 45 Alzahrani et al. 2024 | meta-analysis | Vitamin B12 supplementation (vitamin B12 complex); vs. Control groups of included RCTs | Cognitive memory function: no difference (average standardized mean difference of -0.03 (95% confidence interval (CI): -0.07 to 0.01)); Depressive symptoms: no difference (average standardized mean difference of -0.01 (95% CI: -0.0773 to 0.0525)) |
| 49 Jembere et al. 2024 | systematic review | Vitamin B12 (status, dietary intake, supplementation) | Children's brain and neurodevelopment: unclear; Cognitive, language and motor development: unclear |
Further studies in this area: 52 54 62 68 74 78 90 96 97 99 106 112 113 119 124 127 132 144 163 166 176 177 183 193 194 200 202 218 219 230 231 244 245
Vitamin B12, Blood Formation and Anaemia: Human Studies
In blood formation and anemia, the studies show a mixed picture. For hemoglobin, tablet, sublingual tablet and injection did not differ in a meta-analysis 6. Also in children, administration under the tongue and injection into the muscle yielded the same hemoglobin values 101. Before heart operations, a combination of iron as infusion, erythropoietin, vitamin B12 and folic acid reduced the number of blood transfusions compared with placebo in a randomized study 63. It remains open which form and which route are actually superior in which patient group.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Keats et al. 2021 | systematic review · 451,723 participants | Single and multiple micronutrient supplements, including vitamin B12; vs. Supplementation vs. folic acid, iron-folic acid or other controls | Maternal anaemia (IFA vs. folic acid): improved (48% reduction (average RR 0.52, 95% CI 0.41 to 0.66)) |
| 6 Abdelwahab et al. 2024 | meta-analysis · 4,275 participants | Vitamin B12 (various administration routes); vs. Oral vs. intramuscular vs. sublingual | Hemoglobin level: no difference |
| 7 Larvie et al. 2026 | systematic review · 4,083 participants | Oral vitamin B12 supplementation, alone or with other micronutrients; 0.9 µg/day to 150 µg/day; 28 days to 31 months; vs. Placebo | Anaemia: no difference (ARD 21 more per 1000) |
| 14 Finkelstein et al. 2024 | systematic review · 984 participants | oral vitamin B12 supplementation; 5 µg/day to 250 µg/day; 8–16 to 32–38 weeks, from 8–28 weeks' gestation; vs. placebo or no vitamin B12 supplementation | Maternal anaemia: no difference (70.9% versus 65.0%; RR 1.08, 95% CI 0.93 to 1.26) |
| 18 Wirthensohn et al. 2023 | systematic review · 292 participants | — | Mean age at first symptoms (anemia, neurological symptoms): unclear (four months) |
| 19 Abe et al. 2016 | systematic review · 52 participants | Multiple-micronutrient supplement (three or more micronutrients); vs. Placebo or no supplementation | Maternal anaemia: improved |
| 20 Blom et al. 2024 | systematic review · 50 participants | cobalamin (monotherapy); mean 2 months; vs. no control (case series) | Comorbid pernicious anaemia: unclear (32%) |
| 21 Chen et al. 2026 | meta-analysis | Combined treatment with vitamin B12, iron, EPO, folic acid; vs. Placebo and other interventions | Intraoperative blood loss: improved (MD: 126.33 mL, 95% CrI [23.27, 229.49], P < 0.05) |
Further studies in this area: 34 40 61 63 64 80 95 101 102 152 164 169 173 188 195 196 198 203 210 235
Vitamin B12, Pregnancy and Children: Human Studies
In pregnancy, the studies show a mixed picture. Observational studies from India link low vitamin B12 values in pregnant women with more neural tube defects, pregnancy complications and lower birth weight 54. In randomized studies, vitamin B12 promoted the mental development of the children; the effect on birth weight remained open 54. In women undergoing artificial fertilization, a fertility-promoting diet with omega-3, vitamin D, folate and vitamin B12 increased the fertilization rate compared with usual counseling 76. The share of vitamin B12 in this cannot be separated. A meta-analysis found lower vitamin B12 levels in mothers with neural tube defects 38. The evidence strength is high, but the forms and routes examined are inconsistent, and several studies tested vitamin B12 only in combination with other nutrients.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Keats et al. 2021 | systematic review · 451,723 participants | Single and multiple micronutrient supplements, including vitamin B12; vs. Supplementation vs. folic acid, iron-folic acid or other controls | Low birthweight (IFA vs. folic acid): improved (12% reduction (average RR 0.88, 95% CI 0.78 to 0.99)); Low birthweight (MMN vs. iron with or without FA): improved (15% (average RR 0.85, 95% CI 0.77 to 0.93)); Stillbirths (MMN): improved (average RR 0.91; 95% CI 0.86) |
| 14 Finkelstein et al. 2024 | systematic review · 984 participants | oral vitamin B12 supplementation; 5 µg/day to 250 µg/day; 8–16 to 32–38 weeks, from 8–28 weeks' gestation; vs. placebo or no vitamin B12 supplementation | Preterm birth: unclear (RR 0.97, 95% CI 0.55 to 1.74); Low birthweight: unclear (RR 1.50, 95% CI 0.93 to 2.43) |
| 24 Franco et al. 2026 | systematic review | Maternal vitamin B12 status or supplementation, with vitamin D and folic acid; vs. Children with adequate vs. inadequate maternal vitamin B12 status | Child neurodevelopment: improved |
| 38 Nie et al. 2025 | meta-analysis | Maternal blood vitamin B12 (no supplement given); vs. Neural tube defect group vs. non-NTD controls | Maternal blood vitamin B12 level in neural tube defects: worsened (SMD = -0.23, 95% CI (-0.32, -0.14), p < 0.001); Vitamin B12 level in NTD with no folate difference: worsened (SMD: -0.19, 95% CI (-0.28, -0.10)) |
| 54 Behere et al. 2021 | systematic review | Vitamin B12 (form not specified); vs. low vs. higher maternal B12 status; supplementation vs. control | neural tube defects: improved; pregnancy complications: improved; birth weight: improved |
| 58 Kvestad et al. 2026 | randomised controlled · 800 participants | vitamin B-12 or placebo; from early pregnancy to 6 months postpartum; vs. placebo | Infant motor development (TIMP score): worsened; Interaction with plasma folate: unclear (P-interaction = 0.015) |
| 62 Nagpal et al. 2026 | randomised controlled · 531 participants | Daily oral methylcobalamin; 250 µg (group A) vs. 50 µg (group B); From enrolment to 6 months post partum; vs. Higher dose 250 µg versus lower dose 50 µg | Newborn anthropometry, APGAR scores and morbidity: no difference (p>0.05) |
| 76 Ghadimi et al. 2026 | randomised controlled · 180 participants | Pro-fertility diet plus supplement combination with vitamin B12; vitamin B12 500 µg/day; 60 days; vs. general dietary advice plus 500 µg/day folic acid | fertilization rate: improved (0.81 ± 0.16 versus 0.66 ± 0.24; P < 0.001); embryo formation rate: improved (0.79 ± 0.26 versus 0.62 ± 0.30; P < 0.001); number of embryos formed: improved (3.78 ± 2.34 versus 2.22 ± 1.46; P < 0.001) |
Further studies in this area: 93 158 161 162 164 175 181 182 184 187 190 191 192 200 216 221 228 232 236
Vitamin B12: Further Outcomes in Studies
Oral methylcobalamin improved quality of life in a controlled study in type 2 diabetics with long-term metformin intake and diabetic neuropathy 91. For linear growth in children, a systematic review found no difference from placebo 7. For quality of life under oral cyanocobalamin, a controlled study found no difference 130. The evidence strength is high; most of these studies tested methylcobalamin, and it is open whether other forms act the same.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 7 Larvie et al. 2026 | systematic review · 4,083 participants | Oral vitamin B12 supplementation, alone or with other micronutrients; 0.9 µg/day to 150 µg/day; 28 days to 31 months; vs. Placebo | Height/length: no difference (MD -0.19 cm, 95% CI -2.44 to 2.06) |
| 8 Kuo et al. 2025 | meta-analysis · 1,723 participants | Topical vitamin B12 (cobalamin), partly with vitamins D3, E, B3; vs. Placebo | Pruritus severity (all vitamins combined): improved (SMD: -0.578, 95% CI: -0.736 to -0.419, p = 0.000); Pruritus severity (topical vitamin B12 subgroup): improved |
| 9 Yu et al. 2026 | meta-analysis · 1,688 participants | vitamin B12 via acupoint injection; vs. other administration routes of vitamin B12 | fasting blood glucose: no difference (MD -0.18, 95% CI -0.44 to 0.08); 2-h postprandial blood glucose: no difference (MD -0.02, 95% CI -0.36 to 0.33); adverse event incidence (RR 1.44, 95% CI 0.44-4.70) |
| 10 Ran et al. 2024 | meta-analysis · 1,153 participants | Mecobalamin plus alpha-lipoic acid and epalrestat; vs. Monotherapy or dual therapy with the same drugs | Adverse effects (No statistic difference) |
| 13 Li et al. 2025 | meta-analysis · 1,130 participants | Folate and vitamin B12 (dietary intake or serum levels); vs. lower versus higher intake/levels | HPV persistence and CIN progression: improved (SMD = 0.80 [0.65, 0.95]; p < 0.00001; I2 = 0%; GRADE: High) |
| 15 Gupta et al. 2021 | systematic review · 701 participants | Vitamin B12 among other agents; vs. Placebo or other agents | Hearing outcome in noise-induced hearing loss: unclear |
| 16 Shahid et al. 2025 | systematic review · 693 participants | Proton pump inhibitors (PPIs), not vitamin B12; at least 6 months, up to 12 months; vs. no PPI or baseline | Calcium and parathyroid hormone: worsened (declined significantly in a 12-month cohort); Bone turnover markers: worsened (increased despite stable bone mineral density); Magnesium status: unclear (ranging from no change after 12 months to pharmacokinetic alterations without systemic depletion) |
| 17 Ménétrier et al. 2023 | systematic review · 574 participants | No B12 administration; measurement of total B12, holoTC, tHcy, MMA; vs. No comparison; prevalence of abnormal laboratory values | Proportion with increased methylmalonic acid: unclear (79.6% (71.5-87.7%, n = 98)) |
Further studies in this area: 18 29 30 32 35 36 40 42 43 54 55 56 57 60 61 62 64 65 66 67 69 71 77 79 82 83 84 86 87 90 91 92 94 95 97 99 100 103 104 105 108 109 111 115 116 117 119 120 121 122 123 124 126 127 128 130 131 134 137 138 140 142 143 144 148 151 153 156 165 167 169 172 173 174 175 176 178 179 180 181 182 183 189 193 199 204 207 212 217 218 219 230 233 234 238 240 242 243
4. How Is Vitamin B12 Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used oral, sublingual, intranasal, intramuscular, intravenous and subcutaneous preparations of cyanocobalamin, methylcobalamin, adenosylcobalamin and hydroxocobalamin. Methylcobalamin, also called mecobalamin, was mostly used as a tablet, sometimes also as a gel for application. Several studies tested vitamin B12 only as a component of mixtures, for example with folic acid and vitamin B6, with iron and folic acid or with other micronutrients.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Cyanocobalamin plus folate and vitamin B6, optionally with omega-3 fatty acids | Cyanocobalamin 0.02 mg, folate 0.56 mg, vitamin B6 3 mg daily | 5 years | 57 |
| vitamin B-12 or placebo | — | from early pregnancy to 6 months postpartum | 58 |
| Vitamin B12 (1.8 µg) and/or folic acid (150 µg) | 1.8 µg vitamin B12, 150 µg folic acid daily | 6 months supplementation, follow-up after 6-7 years | 59 |
| Vitamin B12 (about 2 RDA) and/or folic acid (about 2 RDA) or placebo | about 2 RDA daily | 6 months supplementation, follow-up 6 years later | 60 |
| Lipid-based nutrient supplement (LNS) with milk/soy protein and whey permeate/maltodextrin | 100 g per day | 12 weeks | 61 |
| Daily oral methylcobalamin | 250 µg (group A) vs. 50 µg (group B) | From enrolment to 6 months post partum | 62 |
| 1 mg vitamin B12 subcutaneously plus iron, erythropoietin, folic acid | 1 mg vitamin B12 subcutaneously once on the day before surgery | Single dose on the day before surgery | 63 |
| Quintuply-fortified salt (QFS) with vitamin B12 | — | 12 months | 64 |
| Mecobalamin (methylcobalamin) versus placebo | — | 12 months follow-up | 65 |
| Intramuscular ultra-high-dose methylcobalamin | 25 mg or 50 mg | up to week 182 | 66 |
| Topical methylcobalamin gel 6% w/w | — | 12 sessions over four weeks | 67 |
| 500 µg methylcobalamin plus 400 µg folic acid or placebo | 500 µg methylcobalamin and 400 µg folic acid daily | 24 months, follow-up at 12 and 24 months | 68 |
| Folic acid 400 µg + vitamin B12 5 µg or placebo | 400 µg folic acid + 5 µg B12 daily | 12 weeks | 69 |
| vitamin B1-6-12 combination or vitamin B12 alone | — | 4 and 12 weeks | 70 |
| oral methylcobalamin versus placebo | 0.5 mg orally, three times daily | maximum 24 weeks | 71 |
5. Is Vitamin B12 Safe? Side Effects in Studies
The studies predominantly report good tolerability of vitamin B12 in the forms and routes investigated. A review on strongly elevated vitamin B12 levels describes antibodies against the transport protein transcobalamin II after supplementation 25.
| Study | Reported side effects |
|---|---|
| 4 Lee et al. 2022 | relatively safe |
| 7 Larvie et al. 2026 | Adverse effects assessed as critical outcome |
| 9 Yu et al. 2026 | no significant difference in adverse events (RR 1.44, 95% CI 0.44-4.70) |
| 10 Ran et al. 2024 | No statistical difference in adverse effects |
| 11 Jiang et al. 2018 | no serious adverse events |
| 12 Jiang et al. 2018 | No serious adverse events with combination therapy |
| 14 Finkelstein et al. 2024 | spontaneous abortion reported, no quantitative data; no clear definition |
| 16 Shahid et al. 2025 | vitamin B12 and calcium depletion, inconsistent magnesium findings |
| 19 Abe et al. 2016 | not reported |
| 25 Fernández-Téllez et al. 2026 | Formation of anti-transcobalamin II autoantibodies after supplementation |
| 30 Yin et al. 2025 | Overall incidence and types of diabetes-related complications |
| 31 Hamza et al. 2025 | oral therapy better tolerated than intramuscular injections |
6. What Remains Open: Limits of the Evidence
- Many studies are short and investigate different forms and routes of administration, which makes direct comparison difficult.
- The transferability to special groups such as pregnant women, children or the very old remains open.
- For the heart and blood vessels, many studies tested only the homocysteine blood level as an intermediate marker, not hard cardiovascular endpoints.
- For memory and mood, the populations and outcome measures are very heterogeneous, so no uniform statement is possible.
7. Bottom Line: What Is Established About Vitamin B12
In controlled trials, vitamin B12 reliably improves vitamin B12 biomarkers in the blood, regardless of whether it is given orally, sublingually or intramuscularly. For nerve damage due to diabetes and for the homocysteine blood level, improvements are also predominantly seen with methylcobalamin or vitamin B12. With a vegan diet without supplementation and with long-term use of proton pump inhibitors, however, the supply is poorer.
The situation is less uniform for memory, mood, blood formation and in pregnancy: here improvements and results without difference stand side by side. Many studies also tested vitamin B12 only in combination with other nutrients, and several were short or investigated different forms and routes. Tolerability is predominantly described as good.
Frequently Asked Questions
How well has Vitamin B12 been studied in humans?
We evaluated 248 human studies on Vitamin B12, including 93 randomised controlled trials and 56 meta-analyses or systematic reviews; the controlled studies include 14,539 participants in total. As of 3 October 2026.
Does Vitamin B12 help with status in vegan diets, older age and with medication? What the studies show
Does Vitamin B12 help with nerves and nerve damage? What the studies show
Does Vitamin B12 help with homocysteine, heart and blood vessels? What the studies show
Does Vitamin B12 help with memory and mood? What the studies show
Does Vitamin B12 help with blood formation and anaemia? What the studies show
Does Vitamin B12 help with pregnancy and children? What the studies show
Which forms of vitamin B12 were investigated in the studies?
Mainly cyanocobalamin, methylcobalamin, adenosylcobalamin and hydroxocobalamin were investigated. Methylcobalamin, also called mecobalamin, was mostly used as a tablet, sometimes also as a gel for application. Hydroxocobalamin was mostly given as an injection.
Does vitamin B12 work with a vegan diet?
Does vitamin B12 help with nerve damage?
In diabetic neuropathy, nerve conduction, vibration perception and pain improved with oral methylcobalamin over one year, while they worsened with placebo 91.
Does vitamin B12 lower the homocysteine blood level?
In adults with vitamin B12 deficiency, the administration of vitamin B12 lowered the homocysteine blood level; oral and sublingual intake did not perform worse than intramuscular injection 531. Vitamin B12 together with folic acid, sometimes additionally with vitamin B6, also lowered homocysteine 222730354143. However, many studies tested only the homocysteine blood level as an intermediate marker, not hard cardiovascular endpoints.
How tolerable is vitamin B12?
The studies predominantly report good tolerability. A review on strongly elevated vitamin B12 levels describes antibodies against the transport protein transcobalamin II after supplementation 25.
Sources
- 1Keats EC, Oh C, Chau T, Khalifa DS, Imdad A, Bhutta ZA · 2021
- 2Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, Al-Kassab-Córdova A, Cabrera-Guzmán JC, Herrera-Añazco P et al. · 2023
- 3Lotti S, Panizza G, Martini D, Marx W, Beasley JM, Colombini B et al. · 2026
- 4Lee CW, Jin JS, Kwon S, Jin C, Cho SY, Park SU et al. · 2022
- 5Mazur M, Ndokaj A, Salerno C, Vallone J, Ardan R, Bietolini S et al. · 2025
- 6Abdelwahab OA, Abdelaziz A, Diab S, Khazragy A, Elboraay T, Fayad T et al. · 2024
- 7Larvie DY, Güitrón Leal CE, Venkatramanan S, Palma Molina XE, Steel LB, Kuriyan R et al. · 2026
- 8Kuo WH, Chang KS, Chang MH, Hsiao Y, Tsai RY · 2025
- 9Yu Y, Zhou T, Li L, Liu X, Yin Y, Yu R · 2026
- 10Ran GL, Li YP, Lu LC, Lan SH · 2024
- 11Jiang DQ, Xu LC, Jiang LL, Li MX, Wang Y · 2018
- 12Jiang DQ, Zhao SH, Li MX, Jiang LL, Wang Y, Wang Y · 2018
- 13
- 14Finkelstein JL, Fothergill A, Venkatramanan S, Layden AJ, Williams JL, Crider KS et al. · 2024
- 15Gupta A, Koochakzadeh S, Nguyen SA, Brennan EA, Meyer TA, Lambert PR · 2021
- 16Shahid MS, Ahmed N, Kamal Z, Nathaniel L, Singla B, Singla S et al. · 2025
- 17
- 18Wirthensohn M, Wehrli S, Ljungblad UW, Huemer M · 2023
- 19Abe SK, Balogun OO, Ota E, Takahashi K, Mori R · 2016
- 20
- 21Chen Y, Shan J, Gao J, Gao Y, Shi J, Ji H · 2026
- 22Liu X, Yang C, Wang X, Liao H, Liu H, Ma J et al. · 2026
- 23Lall G, Zimmermann MB, Schultink W, Larson LM · 2026
- 24Franco L, de Andrade CVF, Margini LV, Sousa N · 2026
- 25Fernández-Téllez B, Franco-Rico JA, Valdez-Martínez E · 2026
- 26Agbalalah T, Rowaiye A, Iseghohi F · 2026
- 27Li M, Ren R, Wang K, Wang S, Chow A, Yang AK et al. · 2025
- 28Xu XM, Ruan JH, Tao T, Xiang SL, Meng RL, Chen X · 2025
- 29Habtie TE, Zemariam AB, Dagnaw BW, Alamaw AW, Feleke SF, Adisu MA · 2025
- 30
- 31Hamza Ali AA, Mohamed FHA, Hago S, Elsadig Elgali IF, Sherfeldin Mohammed HE, Mirghani RG · 2025
- 32Deng XL, Wu R, Lin XX, Liang JJ, Huang HW · 2025
- 33
- 34Sachdeva M, Purohit A, Malik M, Jain L, Pradhan P, Mathew JL · 2025
- 35Benvidi H, Shafieizadegan S, Gholaminejad A · 2025
- 36
- 37Clemente-Suárez VJ, Redondo-Flórez L, Martín-Rodríguez A, Curiel-Regueros A, Rubio-Zarapuz A, Tornero-Aguilera JF · 2025
- 38Nie L, Liu X, Li X, Ren Z, Cheng X, Wu Y et al. · 2025
- 39Nguyen NTH, Chen YC, Nhu NT, Bao HB, Hsu CY, Das A et al. · 2025
- 40Akinwumi FE, Akinyemi AO, Akangbe B, Odeniran OM, Sehkar J, Olajimbiti CO et al. · 2025
- 41Zhao Y, Ge Y, Zhang Z, Tan C, Lu Y, Guo X et al. · 2025
- 42Mibielli MAN, Suchmacher M, Geller M, Mezitis SGE, Nunes CP, Sintoveter A · 2025
- 43Lee CY, Chan L, Hu CJ, Hong CT, Chen JH · 2024
- 44Keykha E, Tahmasebi E, Hadilou M · 2024
- 45
- 46Wang Q, Xie H, Wang Z, Huang R, Xu M, Li Y et al. · 2024
- 47Desmond MA, Fewtrell MS, Wells JCK · 2024
- 48Niklewicz A, Hannibal L, Warren M, Ahmadi KR · 2024
- 49
- 50Bärebring L, Lamberg-Allardt C, Thorisdottir B, Ramel A, Söderlund F, Arnesen EK et al. · 2023
- 51Koller A, Rohrmann S, Wakolbinger M, Gojda J, Selinger E, Cahova M et al. · 2023
- 52Alruwaili M, Basri R, AlRuwaili R, Albarrak AM, Ali NH · 2023
- 53Karedath J, Batool S, Arshad A, Khalique S, Raja S, Lal B et al. · 2022
- 54Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS · 2021
- 55Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P et al. · 2018
- 56Meolie AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguillard RN et al. · 2005
- 57Andreeva VA, Touvier M, Kesse-Guyot E, Julia C, Galan P, Hercberg S · 2012
- 58Kvestad I, Ulak M, McCann A, Chandyo RK, Hysing M, Schwinger C et al. · 2026
- 59Manapurath R, Strand TA, Chowdhury R, Kvestad I, Yajnik CS, Bhandari N et al. · 2023
- 60Taneja S, Chowdhury R, Kvestad I, Bhandari N, Strand TA · 2023
- 61Mutumba R, Pesu H, Mbabazi J, Greibe E, Nexo E, Olsen MF et al. · 2024
- 62Nagpal J, Mathur M, Rawat S, Singhal A, Pant R, Shah A et al. · 2026
- 63Spahn DR, Schoenrath F, Spahn GH, Seifert B, Stein P, Theusinger OM et al. · 2019
- 64Long JM, Goh YE, Duggal M, Das R, Manger MS, Jamwal M et al. · 2026
- 65Arunakul M, Leesakul C, Samornpitakul P, Kulalert P, Apivatgaroon A, Arunakul P · 2026
- 66Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y et al. · 2019
- 67Khan IA, Bibi I, Bukhari KA, Khan MK · 2026
- 68Gong X, Shi L, Wu Y, Luo Y, Kwok T · 2022
- 69Martinez-Morata I, Parvez F, Wu H, Eunus M, Goldsmith J, Ilievski V et al. · 2024
- 70
- 71Xia Y, Zhu Y, Ling L, Xu F, Yang Y, Ye J et al. · 2025
- 72Li S, Chen X, Li Q, Du J, Liu Z, Peng Y et al. · 2016
- 73Amato B, Compagna R, Amato M, Gallelli L, de Franciscis S, Serra R · 2015
- 74van Soest APM, van de Rest O, Witkamp RF, Cederholm T, de Groot LCPGM · 2022
- 75Zhao X, An X, Cui Y, Dong L, Fang Z, Zheng Z et al. · 2025
- 76Ghadimi Yari M, Ghasemi-Tehrani H, Feizi A, Ziaei R, Derakhshan M, Rouhani MH · 2026
- 77Aburayyan W, Zakaraya Z, Hamad M, Majali IS, Abu Dayyih W, Seder N et al. · 2025
- 78van der Burg KP, Cribb L, Firth J, Karmacoska D, Mischoulon D, Byrne GJ et al. · 2020
- 79Perva IT, Simina IE, Bende R, Motofelea AC, Chirita Emandi A, Andreescu N et al. · 2024
- 80Singh SK, Arora R, Pramanik SK, Kumar A, Singh A, Khanna S et al. · 2026
- 81Savic-Hartwig M, Kerlikowsky F, van de Flierdt E, Hahn A, Schuchardt JP · 2024
- 82Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y et al. · 2022
- 83
- 84Thompson L, Goh YE, Jamwal M, Singh BL, Brar GK, Arnold CD et al. · 2025
- 85Kerlikowsky F, Krüger K, Hahn A, Schuchardt JP · 2025
- 86Kerlikowsky F, Krüger K, Hahn A, Schuchardt JP · 2023
- 87Zhang L, Zhang Y, Yang D, Yang C, Rong X, Li X et al. · 2026
- 88Jeenia FT, Sojib FA, Rahman MS, Ara T, Khan R, Tanin MJU · 2021
- 89Sharma C, Kaur I, Singh H, Grover IS, Singh J · 2021
- 90Li C, Mao W, Zhang L, Zhang X, Wu H, Zhang G et al. · 2024
- 91Didangelos T, Karlafti E, Kotzakioulafi E, Margariti E, Giannoulaki P, Batanis G et al. · 2021
- 92Fu AS, Osman F, Cameron-Smith D, Lam NYL, Mehta KA, Leow MK et al. · 2026
- 93Khare SP, Madhok A, Patta I, Sukla KK, Wagh VV, Kunte PS et al. · 2021
- 94Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C, Giannoulaki P et al. · 2020
- 95Satapathy S, Bandyopadhyay D, Patro BK, Khan S, Naik S · 2020
- 96Crosta F, Stefani A, Melani F, Fabrizzi P, Nizzardo A, Grassi D et al. · 2020
- 97Jung YP, Earnest CP, Koozehchian M, Cho M, Barringer N, Walker D et al. · 2017
- 98Xu G, Tang W, Zhou C, Xu J, Cheng C, Gong W et al. · 2023
- 99
- 100Sheng GB, Su H, Li HL, Bao R, Liu G, Kong Y et al. · 2020
- 101Devi NN, Bansal U, Yerramilli NP, Singh GK, Rastogi AK, Singh VA · 2026
- 102Zerback T, Koeder C, Weder S, Sputtek A, Eckert GP, Keller M · 2025
- 103Zainal NA, Abdul Rashid AM, A Rauf AL, Yusof Khan AHK, Wan Sulaiman WA, Basri H · 2025
- 104Xu J, Zhang Q, Xue N, Zhang C, Xu W · 2025
- 105Chen JF, Chen LY, Zheng X, Yang Y, Chen YT, Zheng MR · 2022
- 106Schneider N, Bruchhage MMK, O'Neill BV, Hartweg M, Tanguy J, Steiner P et al. · 2022
- 107Budoff MJ, Ahmadi N, Gul KM, Liu ST, Flores FR, Tiano J et al. · 2009
- 108
- 109Lu C, Shen Q, Deng D, Zhang Y, Wang P, Shao X et al. · 2025
- 110Association of Plasma Folate, Vitamin B12, and Betaine With Total Homocysteine in Pregnancy, and Effect Modification Due to Folic Acid Versus Natural Folate Supplementation· 2022
- 111Kirsch SH, Herrmann W, Kruse V, Eckert R, Gräber S, Geisel J et al. · 2015
- 112Zajac IT, Herreen D, Bastiaans K, Dhillon VS, Fenech M · 2018
- 113Vijayakumar TM, Pavitra K, Muthunarayanan L · 2017
- 114Pokushalov E, Ponomarenko A, Bayramova S, Garcia C, Pak I, Shrainer E et al. · 2024
- 115Lederer AK, Hannibal L, Hettich M, Behringer S, Spiekerkoetter U, Steinborn C et al. · 2019
- 116da Mota JCNL, Carvalho LM, Souza LL, Ribeiro AA, Pinhel MAS, Nonino CB et al. · 2026
- 117Stücker M, Pieck C, Stoerb C, Niedner R, Hartung J, Altmeyer P · 2004
- 118Ghandour H, Bagley PJ, Shemin D, Hsu N, Jacques PF, Dworkin L et al. · 2002
- 119Kesavaraja S, Veluvali S, Lingan R, Chandradhara D · 2026
- 120
- 121Mansour A, Amrollahi Bioky A, Gerami H, Khorasanian AS, Esmaeili AH, Fateh HR et al. · 2026
- 122Fogagnolo P, Melardi E, Tranchina L, Rossetti L · 2020
- 123Collins PB, Earnest CP, Dalton RL, Sowinski RJ, Grubic TJ, Favot CJ et al. · 2017
- 124Jung YP, Earnest CP, Koozehchian M, Galvan E, Dalton R, Walker D et al. · 2017
- 125Sil A, Kumar H, Mondal RD, Anand SS, Ghosal A, Datta A et al. · 2018
- 126Nistico SP, Del Duca E, Tamburi F, Pignataro E, De Carvalho N, Farnetani F et al. · 2017
- 127Martínez-Noguera FJ, Alcaraz PE, González Blanc FJ, Huyghe TG, Marín-Pagán C · 2026
- 128Abusamak M, Pérez-González F, Ruiz LV, Sáez-Alcaide LM, Al-Waeli H, García-Denche JT et al. · 2026
- 129Kashyap S, Gowda P, Pasanna RM, Sivadas A, Sachdev HS, Kurpad AV et al. · 2024
- 130Insin P, Chaiwongsa T, Prueksaritanond N · 2026
- 131Santos SS, da Costa LATJ, Araripe TSO, Reges BDLO, Ximenes HMA, Moreira ACOM · 2026
- 132Chen CH, Chiu CC, Chiu YH, Chang CH, Chang YH, Huang MC et al. · 2026
- 133Conti G, Kalo AW, Ujjan I, Aslam A, Khan A, Memon NM et al. · 2026
- 134
- 135Shen Q, Deng D, Li G, Ruan J, Shao X, Wang P et al. · 2025
- 136Khan A, Hussain M, Ahmed A, Nazir N, Malik MK, Saeed N · 2025
- 137Orimadegun BE, Ademola AA, Asinobi AO · 2025
- 138He C, Li J, Hu W, Xiao B, Fan T, Zhou J et al. · 2024
- 139Memon NM, Conti G, Brilli E, Tarantino G, Chaudhry MNA, Baloch A et al. · 2024
- 140Vinod Kumar M, Sankarapandian M, Erhardt J · 2022
- 141Pellinen T, Päivärinta E, Isotalo J, Lehtovirta M, Itkonen ST, Korkalo L et al. · 2022
- 142Xu G, Zhou CS, Tang WZ, Xu J, Xu G, Cheng C et al. · 2020
- 143Kopets R, Kuibida I, Chernyavska I, Cherepanyn V, Mazo R, Fedevych V et al. · 2020
- 144Strike SC, Carlisle A, Gibson EL, Dyall SC · 2016
- 145Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trialMazza A, Cicero AF, Ramazzina E, Lenti S, Schiavon L, Casiglia E et al. · 2016
- 146Vasudevan D, Naik MM, Mukaddam QI · 2014
- 147[Clinical observation of post-herpetic neuralgia treated with TCM herbal cupping therapy]Wu X, Hu H, Guo L, Wang H · 2013
- 148Ostojic SM, Niess B, Stojanovic M, Obrenovic M · 2013
- 149Holm PI, Bleie Ø, Ueland PM, Lien EA, Refsum H, Nordrehaug JE et al. · 2004
- 150Prognostic Impact of Serum Homocysteine-Lowering Therapy on Patients with Hemorrhagic Stroke and Its Influence on National Institutes of Health Stroke Scale and China Stroke Scale ScoresAn X, Du X, Yang B, Zhai N, Cui L · 2024
- 151Obeid R, Kirsch SH, Kasoha M, Eckert R, Herrmann W · 2011
- 152Dutta HK, Barman MP, Gupta P, Kotoky MJ, Acharyya BK, Gogoi JC et al. · 2025
- 153Shan Z, Liu M, Zhang L, Zhang Y, Huang W, Yang L et al. · 2025
- 154Demirci F, Yıldırım O, Demirci A, Akan P · 2026
- 155Aboshaiqah A, Aboshaiqah B, Alharbi NM, Almunyif TI, Binghanim SD, Almejalli AK · 2024
- 156Tang F, Qiu H, Liu Y, Guo J, Huang Z, Fang S et al. · 2024
- 157Eken Y, Tekin N, Şahin F, Tay İ, Yıldırım Saral N, Serteser M et al. · 2026
- 158Cruz-Rodríguez J, Canals-Sans J, Jardí C, Arija V · 2026
- 159Bjørkevoll SMG, O'Keeffe M, Konijnenberg C, Solvik BS, Sødal AF, Kaldenbach S et al. · 2025
- 160Schwinger C, Sharma S, Chandyo RK, Hysing M, Kvestad I, Ulak M et al. · 2021
- 161John SE, Azizi K, Hancy A, Twin'omujuni A, Katana D, Shine J et al. · 2023
- 162Charaimuriya B, Agarwal M, Shullai WK, Ruram AA, Sarma A · 2025
- 163Domínguez-López I, Casas R, Chiva-Blanch G, Martínez-González MÁ, Fitó M, Ros E et al. · 2023
- 164Gοugοutsi V, Pouliakis A, Argyrios T, Tolia M, Nazos NA, Panagopoulos P et al. · 2024
- 165Kaji R, Nishi Y, Ishida T, Takase T, Ueda T, Maeda T et al. · 2026
- 166Zhou L, Bai X, Huang J, Tan Y, Yang Q · 2023
- 167Stoffregen CC, Odin EA, Carlsson GU, Kurlberg GK, Björkqvist HG, Tångefjord MT et al. · 2016
- 168Habib A, Idrus H, Malik NAA, Nor AM, Nasohah SM, Moey LH et al. · 2024
- 169Ryan JJ, Hanes DA, Bradley RD, Contractor N · 2019
- 170Verma A, Rizvi S, Saif M, Chouhan V, Jaiswal S · 2026
- 171Mesgarankarimi A, Rezapour M, Tabrizi N · 2025
- 172Kang Y, Yang T, Chen X, Min Z, Tang C, Zhang L et al. · 2025
- 173Souissi S, Ayari M, Abdellali I, Bourguiba R, Belakhal S, Jomni T et al. · 2024
- 174
- 175Stepien KM, Sykut-Cegielska J, Sloan J, Piazzon F, Bick S, Bouchereau J et al. · 2026
- 176Chen IW, Chang LC, Lai YC, Hung KC · 2026
- 177Gordon S, Hoey L, McNulty H, Keenan J, Pangilinan F, Brody LC et al. · 2025
- 178Wang Y, Liu N, Wang T, Liu Y, Yin H, Qu Y · 2025
- 179Zubair AS, Saab L, Scharer K, Khokhar B · 2024
- 180Liu K, Chen Y, Chen J, Chen W, Sun X, Mao Y et al. · 2024
- 181Huemer M, Simma B, Fowler B, Suormala T, Bodamer OA, Sass JO · 2005
- 182Ayoub G · 2026
- 183Lopez-Ruiz AA, Anastopulos FD, Trinchet LP, Maloney J, Wie C, Viswanath O et al. · 2026
- 184Andonotopo W, Bachnas MA, Dewantiningrum J, Adi Pramono MB, Sulistyowati S, Hariyasa Sanjaya IN et al. · 2026
- 185Marandola M, Napoli G, Leggeri S, Lombardi C, Urbani A, Baroni S · 2026
- 186Panou T, Asimakopoulos B · 2026
- 187Yang R, Li G · 2026
- 188Saini AG, Gunasekaran PK, Prasad AN · 2026
- 189Pancheva R, Dzhogova M, Dimitrov L, Nikolova M, Mihaylova G, Panayotova V et al. · 2026
- 190Mathew AR, Selita E, Regano C, Bianco C, Corsetti V, Cavallucci V et al. · 2026
- 191Ota K, Takahashi T · 2026
- 192Su J, Cai C, Zhang Y, Wang D, Yan S, Yao X · 2026
- 193Papazachariou A, Papakitsou I, Malikides V, Filippatos TD · 2026
- 194
- 195Xu L, Gao Y, Li Y, Wang Z · 2026
- 196Chougule S, T M, Mohite A, Choudhary V, Thangvelu S, Datkhile K et al. · 2026
- 197Umar M, Franjieh K, White AL, Ward-Dones E, Ismael S, Roskey RC et al. · 2026
- 198Farrell CC, Burkhead JL, Collins JF, Gernand AD, Green TJ, Hoey L et al. · 2026
- 199Srisuwatchari W, Norchai P · 2026
- 200Zwierz M, Suprunowicz M, Mrozek K, Pietruszkiewicz J, Oracz AJ, Konarzewska B et al. · 2025
- 201Brown KH, Hess SY, Moore SE, Combs GF, Cashman KD, McNulty H et al. · 2025
- 202Han A, Almeida L, Anand N, Salloum IM, Kanaan S, Gadad BS et al. · 2025
- 203Malhotra A, Lakade A · 2025
- 204
- 205
- 206Huang L, Huhulea EN, Enwere C, Aifuwa E, Frishman WH, Aronow WS · 2025
- 207Porcaro G, Calcagno M, Tinelli A · 2025
- 208
- 209Du F, Alhaskawi A, Zou X, Zhou W, Lu H · 2025
- 210Robinson SR, Trivedi MS, Fayet-Moore F · 2025
- 211Halim Z, Huang Y, Lee ZY, Lew CCH · 2024
- 212Kaji R, Izumi Y, Oki R · 2024
- 213Chungchunlam SMS, Moughan PJ · 2024
- 214Carretero-Krug A, Montero-Bravo A, Morais-Moreno C, Puga AM, Samaniego-Vaesken ML, Partearroyo T et al. · 2024
- 215Fernandes S, Oliveira L, Pereira A, Costa MDC, Raposo A, Saraiva A et al. · 2024
- 216Sfakianoudis K, Zikopoulos A, Grigoriadis S, Seretis N, Maziotis E, Anifandis G et al. · 2024
- 217Simonenko SY, Bogdanova DA, Kuldyushev NA · 2024
- 218Rekik A, Santoro C, Poplawska-Domaszewicz K, Qamar MA, Batzu L, Landolfo S et al. · 2024
- 219Kennedy KP, Alexander JL, Garakani A, Gross LS, Mintz DL, Parikh T et al. · 2024
- 220Green strength: The role of micronutrients in plant-based diets for athletic performance enhancementAyaz A, Zaman W, Radák Z, Gu Y · 2024
- 221Arcot A, Walker RE, Gallagher K, Klatt KC, Gernand AD · 2024
- 222Poulidou V, Liampas I, Arnaoutoglou M, Dardiotis E, Siokas V · 2024
- 223Sandoval Leiva T, Muñoz Y, Tabilo Aguirre L, Estay Castillo P · 2024
- 224Łuszczki E, Boakye F, Zielińska M, Dereń K, Bartosiewicz A, Oleksy Ł et al. · 2023
- 225Jakše B, Fras Z, Fidler Mis N · 2023
- 226Wu HHL, McDonnell T, Chinnadurai R · 2023
- 227
- 228Bjørke-Monsen AL, Lysne V · 2023
- 229Shirode PS, Parekh AD, Patel VV, Vala J, Jaimalani AM, Vora NM et al. · 2023
- 230Batista KS, Cintra VM, Lucena PAF, Manhães-de-Castro R, Toscano AE, Costa LP et al. · 2022
- 231Lauer AA, Grimm HS, Apel B, Golobrodska N, Kruse L, Ratanski E et al. · 2022
- 232Heland S, Fields N, Ellery SJ, Fahey M, Palmer KR · 2022
- 233Pyrgioti EE, Karakousis ND · 2022
- 234Lacombe V, Lenaers G, Urbanski G · 2022
- 235Kósa M, Galla Z, Lénárt I, Baráth Á, Grecsó N, Rácz G et al. · 2022
- 236
- 237Marrone G, Guerriero C, Palazzetti D, Lido P, Marolla A, Di Daniele F et al. · 2021
- 238Fila M, Chojnacki C, Chojnacki J, Blasiak J · 2021
- 239Cordaro M, Siracusa R, Fusco R, Cuzzocrea S, Di Paola R, Impellizzeri D · 2021
- 240Vaccaro JA, Naser SA · 2021
- 241[Extra hospital use of nitrous oxide for recreational purposes]Domont P, Debaize S · 2020
- 242Buesing S, Costa M, Schilling JM, Moeller-Bertram T · 2019
- 243Hankey GJ · 2018
- 244Troesch B, Weber P, Mohajeri MH · 2016
- 245Nyaradi A, Li J, Hickling S, Foster J, Oddy WH · 2013
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.